Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden

American Journal of Epidemiology

Volumn 171, Issue 2, 2010, Pages 198-205

  Cole, Stephen R ^a   Napravnik, Sonia ^a,b   Mugavero, Michael J ^c   Lau, Bryan ^d   Eron Jr , Joseph ^b   Saag, Michael S ^c  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c University of Alabama at Birmingham   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acquired immunodeficiency syndrome; HIV; HIV infections; Viral load; Viremia

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE INCIDENCE; EPIDEMIOLOGY; HEALTH CARE; HUMAN IMMUNODEFICIENCY VIRUS; MORTALITY; VIRUS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; RACE; SEROCONVERSION; VIREMIA; VIRUS LOAD;

ADULT; HIV INFECTIONS; HIV-1; HUMANS; MALE; VIRAL LOAD; VIREMIA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 73949092992     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp347     Document Type: Article

References (43)

1. Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002; 360(9327):119-129. (Pubitemid 34786200)
2. Cole SR, Hernán MA, Anastos K, et al. Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol. 2007;166(2):219-227.
3. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300(5): 555-570
4. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293-299.
5. 3. J Acquir Immune Defic Syndr. 2007;44(2): 179-187.
6. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection [electronic article]. PLoS Med. 2008;5(10):e203.
7. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987; 126(2):310-318
8. -1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
9. Cain LE, Cole SR, Chmiel JS, et al. Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters. Am J Epidemiol. 2006;163(4): 310-315.
10. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4\+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946-954.
11. Harrell FE Jr. Regression Modeling Strategies. New York, NY: Springer Publishing Company; 2001:49.
12. Prignot J. Quantification and chemical markers of tobacco-exposure. Eur J Respir Dis. 1987;70(1):1-7.
13. Lial ML, Greenwell RN, Ritchey NP. Finite Mathematics and Calculus. New York, NY: Pearson Education, Inc; 2002:854.
14. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
15. Harrell FE Jr, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst. 1988;80(15):1198-1202.
16. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov EB, Csaki F, eds. 2nd Annual Symposium on Information Theory and Control. Budapest, Hungary: Akademia Kiado; 1973:267-281.
17. Burnham KP, Anderson DR. Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res. 2004;33(2):261-304.
18. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4\+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996;334(7):426-431.
19. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272(5265):1167-1170.
20. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med. 1996;2(6):625-629.
21. Mellors JW, Margolick JB, Phair JP, et al. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA. 2007;297(21):2349-2350.
22. Hockett RD, Kilby JM, Derdeyn CA, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med. 1999;189(10):1545-1554.
23. Rodŕiguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006;296(12):1498-1506.
24. Lima VD, Fink V, Yip B, et al. Association between HIV-1 RNA level and CD4 cell count among untreated HIV-infected individuals. Am J Public Health. 2009;99(suppl 1):S193-S196.
25. Anastos K, Barrón Y, Cohen MH, et al. The prognostic importance of changes in CD4\+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med. 2004;140(4):256-264.
26. Zoufaly A, Stellbrink HJ, Heiden MA, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis. 2009; 200(1):79-87.
27. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815- 1826.
28. Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Stat Med. 1992;11(14-15):1825-1839.
29. Lyles RH, Muñoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after serocon-version and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis. 2000; 181(3):872-880.
30. Rothman KJ. Induction and latent periods. Am J Epidemiol. 1981;114(2):253-259
31. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293-299.
32. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146(2):87-95.
33. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48(5): 590-598.
34. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr. 2006;43(1):27-34.
35. Phillips AN, Gazzard B, Gilson R, et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS. 2007;21(13):1717-1721.
36. Sackoff JE, Hanna DB, Pfeiffer MR, et al. Causes of death among persons with AIDS in the era of highly active antire-troviral therapy: New York City. Ann Intern Med. 2006;145(6): 397-406.
37. Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS. 2006;20(5):741-749.
38. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4(\+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest. 1999;103(10):1391-1398.
39. Tebas P, Henry WK, Matining R, et al. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk [electronic article]. PLoS One. 2008;3(4):e2021.
40. May M, Sterne JA, Shipley M, et al. A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int J Epidemiol. 2007;36(6): 1309-1318.
41. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007;45(8):1074-1081.
42. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20(4):488-495
43. Collaborative Group on AIDS Incubation and HIV Survival Including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet. 2000;355(9210):1131-1137.